Expression of cyclin A and topoisomerase IIα of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival

Histopathology

Volumn 42, Issue 4, 2003, Pages 395-402

  Park, S H ^a   Suh, Yoen Lim ^b,c  

^a Inje University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Cyclin A; Cyclin D1; MIB 1 (Ki67); Oligodendroglioma; Topoisomerase II

Indexed keywords

CYCLIN A; CYCLIN D1; DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT;

ARTICLE; BRAIN TISSUE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SATELLITE CELL; TISSUE SECTION;

ADULT; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CYCLIN A; CYCLIN D1; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; SURVIVAL RATE;

EID: 0037393429     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01597.x     Document Type: Article

References (28)

1. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999: 45; 1279-1291.
2. Kolles H, Niedermayer I, Feiden W. Grading of astrocytomas and oligodendrogliomas. Pathologe 1998: 19; 259-268.
3. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 1998: 90; 1473-1479.
4. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 2000: 18; 636-645.
5. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001: 12; 73-90.
6. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur. J. Cancer 1999: 35; 1886-1894.
7. Wilson CS, Medeiros LJ, Lai R et al. DNA topoisomerase II alpha in multiple myeloma: a marker of cell proliferation and not drug resistance. Mod. Pathol. 2001: 14; 886-891.
8. Ren Y, Munyer P, Kepes JJ et al. Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. Appl. Immunohistochem. Molec. Morph. 2001; 9: 14-18.
9. Chakrabarty A, Bridges LR. Immunohistochemical analysis of cyclin A in astrocytic tumours. Neuropathol. Appl. Neurobiol. 1998: 24; 239-245.
10. Kros JM, Hop WCJ, Godschalk JCJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996: 78; 1107-1113.
11. Coons SW, Johnson PC, Pearl DC. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997; 41: 878-884.
12. Schiffer D, Dutto A, Cavalla P et al. Prognostic factors in oligodendroglioma. Can. J. Neurol. Sci. 1997: 24; 313-319.
13. Hagel C, Krog B, Laas R, Stavrou DK. Prognostic relevance of TP53 mutation, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas. J. Exp. Clin. Cancer Res. 1999: 18; 305-309.
14. Reis-Filho JS, Faoro LN, Carrilho C, Bleggi-Torres LF, Schmitt FC. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma. Cancer 2000: 88; 862-869.
15. Cavalla P, Piva R, Bortolotto S et al. p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathol. (Berl.) 1999: 98; 629-634.
16. Sato K, Schauble B, Kleihues P, Ohgaki H. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int. J. Cancer 1996: 66; 305-308.
17. Miettinen HE, Jarvinen TA, Kellner U et al. High topoisomerase II alpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas. Neuropathol. Appl. Neurobiol. 2000: 26; 504-512.
18. Kleihues P, Cavenee WK. Tumors of the nervous system: pathology & genetics. World Health Organization International Classification of Tumors. Lyon: IARC Press. 2000: 56-64.
19. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21 (WAF1). Oral Oncol. 2000: 36; 3-7.
20. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr. 1995: 5; 127-156.
21. Peters G. The D-type cyclins and their role in tumorigenesis. J. Cell Sci. Suppl. 1994: 18; 89-96.
22. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 1998: 52; 1-15.
23. Callanan M, Leroux D, Magaud JP, Rimokh R. Implication of cyclin D1 in malignant lymphoma. Crit. Rev. Oncog. 1996: 7; 191-203.
24. Buschges R, Weber RG, Actor B, Lichter P, Collins VP, Reifenberger G. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol. 1999: 9; 435-442.
25. Chakrabarty A, Bridges LR, Gray S. Cyclin D1 in astrocytic tumours: an immunohistochemical study. Neuropathol. Appl. Neurobiol. 1996: 22; 311-316.
26. Prosperi E, Stivala LA, Scovassi AI, Bianchi L. Cyclins: relevance of subcellular localization in cell cycle control. Eur. J. Histochem. 1997: 41: 161-168.
27. Wolowiec D, Ffrench M. Cyclins A and B: redundancy and specificity. Pathol. Biol. (Paris) 1993: 41; 547-553.
28. Korshunov A, Golanov A. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas. Arch. Pathol. Lab. Med. 2001: 125; 892-898.